伐昔洛韦长期抑制治疗复发性生殖器疱疹的疗效观察

伐昔洛韦是治疗复发性生殖疱疹(GH)的一线药物,疗效确切,不良反应轻微.在2009年以前,国内的间歇治疗和长期抑制治疗主要采用300 mg[1],而国外学者研究发现,500 mg伐昔洛韦长期抑制疗法对生殖器疱疹的治疗具有良好临床疗效[2].     

伐昔洛韦长期抑制治疗复发性生殖器疱疹的疗效观察

伐昔洛韦是治疗复发性生殖疱疹(GH)的一线药物,疗效确切,不良反应轻微.在2009年以前,国内的间歇治疗和长期抑制治疗主要采用300 mg[1],而国外学者研究发现,500 mg伐昔洛韦长期抑制疗法对生殖器疱疹的治疗具有良好临床疗效[2].     

伐昔洛韦长期抑制治疗复发性生殖器疱疹的疗效观察

伐昔洛韦是治疗复发性生殖疱疹(GH)的一线药物,疗效确切,不良反应轻微.在2009年以前,国内的间歇治疗和长期抑制治疗主要采用300 mg[1],而国外学者研究发现,500 mg伐昔洛韦长期抑制疗法对生殖器疱疹的治疗具有良好临床疗效[2].     

补中益气汤加减治疗掌跖脓疱病性关节炎1例

掌跖脓疱病性关节炎是一种少见的皮肤病变相关的关节疾病,单纯西药治疗本病不良反应较大,且易复发.中药治疗本病具有独特优势,长期应用疗效稳定,安全性高.利用补中益气汤加减治疗掌跖脓疱病伴胸肩部疼痛患者1例取得良好疗效。     

秋水仙碱在皮肤病治疗中的进展

秋水仙碱为一天然产物,自百合科植物秋水仙中提取,其应用于临床历史悠久,具有抗有丝分裂、抗炎症、免疫抑制作用.痛风和家族性地中海热是秋水仙碱的绝对适应证,近年来在临床应用中发现,秋水仙碱治疗某些特定皮肤病,如某些中性粒细胞浸润性皮肤病、银屑病、大疱性皮肤病等有良好的疗效.秋水仙碱低剂量时一般耐受良好,不良反应少,但过量使用时毒副作用较多,因此,临床应用时需注意药物的不良反应及药物间的相互作用,并及时监测相关指标.     

激光治疗甲真菌病的作用机制与应用进展

甲真菌病目前以传统的药物治疗为主，存在长期用药的不良反应及患者依从性欠佳等问题。近年来，逐渐尝试应用激光治疗甲真菌病，取得了良好的疗效并弥补了上述不足。该文对临床常用激光治疗甲真菌病的作用机制，单用激光治疗及联合外用抗真菌药、系统抗真菌药治疗甲真菌病的研究进展，激光疗效的可能影响因素与不良反应进行综述。     

窄谱中波紫外线治疗白癜风

白癜风是一种常见的色素脱失性疾病,应用窄谱中波紫外线治疗有一定疗效.比较单独应用窄谱中波紫外线、窄谱中波紫外线联合其他药物的临床疗效及不良反应.窄谱中波紫外线是治疗成人或儿童泛发性白癜风以及严重影响患者生活质量的限局性白癜风安全有效的方法;尤其对于肤色较深患者及面颈部的皮损,疗效更佳.对于窄谱中波紫外线联合其他药物的利弊及长期应用的风险,需要进一步评估.     

伐昔洛韦长期抑制治疗复发性生殖器疱疹的疗效观察

伐昔洛韦是治疗复发性生殖疱疹（GH）的一线药物,疗效确切,不良反应轻微。在2009年以前,国内的间歇治疗和长期抑制治疗主要采用300mg[1],而国外学者研究发现,500mg伐昔洛韦长期抑制疗法对生殖器疱疹的治疗具有良好临床疗效[2]。     

外用他克莫司安全性研究进展

他克莫司是一种大环内酯类免疫抑制剂,作用机制与环孢素相似,由于其相对分子质量较小,可以穿透表皮屏障.外用他克莫司治疗特应性皮炎和其他T细胞介导的皮肤病具有良好的疗效,已成为皮肤科临床药物治疗的新选择,但由于该药具有较强的免疫抑制作用和潜在的系统吸收问题,长期使用的安全性问题倍受人们关注.目前对外用他克莫司不良反应的系统评价较少,概述近几年在国内外报道的外用他克莫司不良反应,为更合理使用该药提供参考.     

自体黑素细胞培养移植治疗白癜风的长期随访观察与研究

目的:观察白癜风患者接受自体黑素细胞培养移植治疗的长期临床疗效与安全性。方法:对6例白癜风患者进行自体黑素细胞培养移植治疗后即随访观察了6~9.5年,并评价其临床疗效与安全性。结果:自体黑素细胞培养移植后的皮损肤色均匀一致,色泽度与周边正常皮肤一致,并且与皮损周边皮肤融合较好,未见明显的不良反应,安全可靠。结论:自体黑素细胞培养移植治疗白癜风患者临床疗效好且无不良反应,安全性可靠,值得临床推广和应用。     

小剂量皮质类固醇冲击治疗SLE83例疗效观察

为探讨治疗ＳＬＥ的更好的投药方式及减少其副作用，采用小剂量皮质类固醇激素冲击治疗轻、中度ＳＬＥ８３例。效果良好。与常规治疗效量相比，其平均住院日明显缩短，治疗１个月后激素平均剂量明显减少（Ｐ＜０．００１），而且副作用较轻。该疗法可以较广泛地应用于治疗轻、中度ＳＬＥ。     

生物制剂治疗SLE的进展

SLE的生物治疗因其特异性针对发病机制的不同环节,已成为SLE治疗的新方向.目前的生物治疗包括B细胞靶向疗法;改变T、B细胞相互作用;抑制相关细胞因子;诱导免疫耐受及补体抑制剂等.仅有小部分生物制剂的临床试验取得预期疗效,其中B细胞靶向疗法较为成功.深入研究SLE不同亚型的作用靶位,优化试验设计,改进评估指标,将研发出更安全有效的药物,并能准确全面评价.

Abstract：

Biologics selectively target the pathogenesis of SLE at different levels, and have become new therapeutic options for SLE. Current biological treatments include B-cell-targeting therapy, alteration of T and B cell interaction, anti-cytokine therapy, induction of immunotolerance, blockade of complement, etc. To date, only a small part of the biologics have received expected outcomes, and B-cell-targeting therapy seems to be the most promising biological approach. To identify the molecular targets in different SLE subtypes, optimize the design of drug trials, improve disease activity evaluation, will contribute to the development of more effective and safe drugs for, as well as to the complete and accurate evaluation of disease activity of, SLE.     

生物制剂治疗系统性红斑狼疮新进展

系统性红斑狼疮是一种表现多样的慢性自身免疫病，可累及全身。糖皮质激素及免疫抑制剂为主的传统药物对部分SLE患者的疗效欠佳，且长期应用毒副作用大。生物制剂的出现为SLE治疗带来新的选择，临床应用中也取得了一定成效。本文就生物制剂在红斑狼疮临床治疗中的新进展作一综述。     

Topical antiandrogens in the treatment of male-pattern baldness

Antiandrogen therapy for androgen-induced baldness is in its infancy. In men, because of side effects, topical antiandrogens appear to hold the most promise. Assessing changes in scalp hair growth may be difficult, however, and hirsutism provides a useful model for testing the efficacy of topical antiandrogens. Systemic administration of 5a-reductase inhibitors may also eventually prove to be helpful in the treatment of male-pattern baldness, but side effects and long-term risks are unknown. In women, systemic antiandrogens appear to be a reasonable option for therapy and produce a good subjective response. Further research is needed, however, ta document the long-term risks and efficacy of systemic antiandrogen therapy in women.     

系统性红斑狼疮伴中枢神经精神障碍20例报告

我院自1970年以来共收治较严重的SLE住院病人59例,现就其中伴有神经精神障碍的20例分析报告如下.     

Pulse glucocorticoids

High-dose intravenous (i.v.) methylprednisolone has been used therapeutically in a number of medical fields to avoid the complications and side effects of long-term glucocorticoid (GC) therapy and because of the perception that high-dose i.v. methylprednisolone may have "special" therapeutic effects. It is possible that aggressive early therapy with GCs allows for a more rapid taper of GCs and therefore prevents some of the dose-related side effects associated with long-term use. Some of the neurologic and rheumatologic literature related to multiple sclerosis and lupus nephritis suggest that i.v. methylprednisolone has therapeutic effects that are different from those of conventional doses of oral prednisone. There is still considerable debate about this in nondermatologic fields, and extrapolation of the role of pulse i.v. methylprednisolone to dermatologic disease, where trials are lacking, is difficult. Given this subset of possible candidates of this therapy as suggested by anecdotal reports, there is at least a rationale for considering the use of this modality in a subset of patients.     

Ästhetische Dermatologie

Younger and younger patients are undergoing aesthetic procedures to achieve "wrinkle-free" aging. This has had great impact on the field of aesthetic dermatology. The rapid development of new indications and filler materials requires a critical approach to the available substances particularly concerning side effects and long-term effects. The quality of the chosen approach depends on the applied filler substance, clear indication the compliance of the patient and the experience of the physician. The growing expectations of patients require a critical analysis of the available therapy options. Botulinum toxin A is one of the preferred treatments for wrinkles secondary to facial expression. In addition there are a variety of biologically inert and completely resorbable filler materials such as collagen and hyaluronic acid and autologous materials such as fat implants or plasma gel available. This article gives an overview about the most common fillers and their use in aesthetic dermatology.     

Atopic eczema complicated by systemic lupus erythematosus

We report two patients with atopic eczema (AE), who developed systemic lupus erythematosus (SLE). Case 1 was a 25-year-old man who developed SLE during treatment of AE in our department. He had a positive antinuclear antibody (ANA) (1:640), anti-ssDNA, anti-SSA and anti-RNP. Case 2 was a 27-year-old man who had a past history of AE. He developed SLE and had a positive ANA (1:320), anti-ssDNA, anti-dsDNA and anti-SSA. Among 33 patients with SLE in our department, four had suffered from AE (12%). There have been a few reports of AE complicated by SLE. Even if it is very rare, like case 1, that two morbid conditions, AE and SLE simultaneously exist in an individual, our findings suggest that it is necessary to measure various autoantibodies in ANA (+) patients with AE and to carefully monitor those patients for long-term development of SLE symptoms if other autoantibodies are positive.     

系统性红斑狼疮患者血清中HHV-8的PCR检测

目的　探讨HHV 8在系统性红斑狼疮 (SLE)中的感染情况及可能的致病机制。方法　应用HHV 8特异性引物片断对 3 4例SLE患者血清进行PCR检测。结果　SLE患者血清HHV 8阳性率为 47% ,显著高于对照组 (P <0 .0 1)。结论　①HHV 8在SLE患者中有较高的感染率 ,有必要进行更深入的研究 ;②SLE患者长期应用激素及免疫抑制剂治疗 ,可能更容易造成各种慢病毒 (包括HHV 8)的持续感染     

天疱疮121例临床分析

目的：加强对天疱疮的认识,提高治疗水平。方法：回顾性分析121例天疱疮患者的临床资料。结果：大部分天疱疮患者通过激素及免疫抑制剂的治疗均能获得临床缓解,免疫抑制剂、血浆置换、大剂量丙种免疫球蛋白冲击治疗等＂辅助疗法＂能减少激素用量及其所产生的远期并发症,自体外周血造血干细胞移植有望根治难治性天疱疮。结论：目前天疱疮的治疗药物仍以激素为主,但由于其副作用,一些新型的治疗方案的研究正积极展开。